2026-04-13T05:40:48Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1957472025-11-20T15:54:20Zcom_2072_1057col_2072_478798col_2072_478917

00925njm 22002777a 4500 dc Rischin, Danny author Harrington, Kevin J. author Greil, Richard author Soulières, Denis author Tahara, Makoto author Castro, Gilberto de author Psyrri, Amanda author Braña, Irene author Neupane, Prakash author Bratland, Åse author Fuereder, Thorsten author Hughes, Brett G.M. author Mesía Nin, Ricard author Ngamphaiboon, Nuttapong author Rordorf, Tamara author Ishak, Wan Zamaniah Wan author Hong, Ruey-Long author González Mendoza, René author Jia, Liyi author Chirovsky, Diana author Norquist, Josephine author Jin, Fan author Burtness, Barbara author 2023-03-21T18:11:11Z 2023-03-21T18:11:11Z 2022-05 2023-03-21T18:11:11Z Objectives: To assess health-related quality of life (HRQoL) with first-line pembrolizumab, pembrolizumab-chemotherapy, or cetuximab-chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the phase 3 KEYNOTE-048 trial (NCT02358031). Materials and methods: HRQoL was measured using the European Organisation for Research and Treatment of Cancer 30-question quality-of-life (EORTC QLQ-C30), the EORTC 35-question quality-of-life head and neck cancer-specific module (EORTC QLQ-H&N35), and the EuroQol 5-dimension 3-level instruments (EQ-5D-3L). Secondary endpoints included mean change from baseline in EORTC QLQ-C30 global health status/quality of life (GHS/QoL) at week 15 and time to deterioration (TTD) in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H&N35 pain and swallowing. Results: Of 882 enrolled participants, 844 received ≥ 1 dose of study treatment and completed ≥ 1 HRQoL assessment; adherence was ≥ 79% at week 15 across treatment groups. At week 15, EORTC QLQ-C30 GHS/QoL scores remained stable; no clinically meaningful between-group differences were observed (least squares mean difference, pembrolizumab vs cetuximab-chemotherapy, 0.24; 95% CI, -3.34 to 3.82; pembrolizumab-chemotherapy vs cetuximab-chemotherapy, 0.40; 95% CI, -3.46 to 4.26). Median TTD in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H&N35 pain and swallowing scores was not reached over 51 weeks across groups, showing stable HRQoL. TTD was similar between groups for EORTC QLQ-C30 GHS/QoL (pembrolizumab vs cetuximab-chemotherapy: HR, 1.38; 95% CI, 0.95-2.00; pembrolizumab-chemotherapy vs cetuximab-chemotherapy: HR, 1.37; 95% CI, 0.94-2.00), as was TTD in EORTC QLQ-H&N35 pain and swallowing scores. Conclusions: Pembrolizumab monotherapy and pembrolizumab-chemotherapy extended OS while maintaining HRQoL, further supporting first-line use for R/M HNSCC. Anticossos monoclonals Quimioteràpia Malalties cròniques Càncer de coll Càncer de cap Monoclonal antibodies Chemotherapy Chronic diseases Neck cancer Head cancer Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048